nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—CYP2C9—Gefitinib—lung cancer	0.043	0.339	CbGbCtD
Epoprostenol—CYP2C9—Teniposide—lung cancer	0.0417	0.329	CbGbCtD
Epoprostenol—PTGIR—pulmonary artery—lung cancer	0.0384	0.43	CbGeAlD
Epoprostenol—CYP2C9—Paclitaxel—lung cancer	0.0233	0.184	CbGbCtD
Epoprostenol—CYP2C9—Cisplatin—lung cancer	0.0187	0.148	CbGbCtD
Epoprostenol—PTGIS—respiratory system—lung cancer	0.0112	0.126	CbGeAlD
Epoprostenol—P2RY12—epithelium—lung cancer	0.00845	0.0948	CbGeAlD
Epoprostenol—PTGIR—respiratory system—lung cancer	0.00645	0.0724	CbGeAlD
Epoprostenol—PTGIS—lung—lung cancer	0.00597	0.0669	CbGeAlD
Epoprostenol—PTGIR—epithelium—lung cancer	0.00539	0.0605	CbGeAlD
Epoprostenol—Dinoprost Tromethamine—HPGDS—lung cancer	0.00486	0.565	CrCbGaD
Epoprostenol—PTGIS—lymph node—lung cancer	0.00408	0.0458	CbGeAlD
Epoprostenol—Dinoprostone—HPGDS—lung cancer	0.00374	0.435	CrCbGaD
Epoprostenol—CYP2C9—mammary gland—lung cancer	0.00346	0.0388	CbGeAlD
Epoprostenol—PTGIR—lung—lung cancer	0.00343	0.0384	CbGeAlD
Epoprostenol—PTGIR—lymph node—lung cancer	0.00234	0.0263	CbGeAlD
Epoprostenol—Dermatitis—Vinorelbine—lung cancer	0.000254	0.00053	CcSEcCtD
Epoprostenol—Abdominal distension—Doxorubicin—lung cancer	0.000254	0.00053	CcSEcCtD
Epoprostenol—Hypotension—Paclitaxel—lung cancer	0.000254	0.000529	CcSEcCtD
Epoprostenol—Headache—Vinorelbine—lung cancer	0.000253	0.000527	CcSEcCtD
Epoprostenol—Syncope—Docetaxel—lung cancer	0.000253	0.000527	CcSEcCtD
Epoprostenol—Sweating—Methotrexate—lung cancer	0.000249	0.00052	CcSEcCtD
Epoprostenol—Palpitations—Docetaxel—lung cancer	0.000249	0.000519	CcSEcCtD
Epoprostenol—Paraesthesia—Etoposide—lung cancer	0.000249	0.000518	CcSEcCtD
Epoprostenol—Haematuria—Methotrexate—lung cancer	0.000248	0.000517	CcSEcCtD
Epoprostenol—Loss of consciousness—Docetaxel—lung cancer	0.000248	0.000517	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000247	0.000516	CcSEcCtD
Epoprostenol—Dyspnoea—Etoposide—lung cancer	0.000247	0.000515	CcSEcCtD
Epoprostenol—Somnolence—Etoposide—lung cancer	0.000246	0.000513	CcSEcCtD
Epoprostenol—Cough—Docetaxel—lung cancer	0.000246	0.000513	CcSEcCtD
Epoprostenol—Insomnia—Paclitaxel—lung cancer	0.000245	0.000512	CcSEcCtD
Epoprostenol—Epistaxis—Methotrexate—lung cancer	0.000245	0.000511	CcSEcCtD
Epoprostenol—Hypersensitivity—Irinotecan—lung cancer	0.000245	0.000511	CcSEcCtD
Epoprostenol—Paraesthesia—Paclitaxel—lung cancer	0.000244	0.000508	CcSEcCtD
Epoprostenol—Dyspnoea—Paclitaxel—lung cancer	0.000242	0.000505	CcSEcCtD
Epoprostenol—Somnolence—Paclitaxel—lung cancer	0.000241	0.000503	CcSEcCtD
Epoprostenol—Decreased appetite—Etoposide—lung cancer	0.000241	0.000502	CcSEcCtD
Epoprostenol—Arthralgia—Docetaxel—lung cancer	0.00024	0.0005	CcSEcCtD
Epoprostenol—Myalgia—Docetaxel—lung cancer	0.00024	0.0005	CcSEcCtD
Epoprostenol—Chest pain—Docetaxel—lung cancer	0.00024	0.0005	CcSEcCtD
Epoprostenol—Pancytopenia—Doxorubicin—lung cancer	0.00024	0.0005	CcSEcCtD
Epoprostenol—Nausea—Vinorelbine—lung cancer	0.00024	0.0005	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Etoposide—lung cancer	0.000239	0.000498	CcSEcCtD
Epoprostenol—Dyspepsia—Paclitaxel—lung cancer	0.000239	0.000498	CcSEcCtD
Epoprostenol—Body temperature increased—Cisplatin—lung cancer	0.000239	0.000498	CcSEcCtD
Epoprostenol—Asthenia—Irinotecan—lung cancer	0.000239	0.000498	CcSEcCtD
Epoprostenol—Fatigue—Etoposide—lung cancer	0.000239	0.000498	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000238	0.000497	CcSEcCtD
Epoprostenol—Pain—Etoposide—lung cancer	0.000237	0.000494	CcSEcCtD
Epoprostenol—Constipation—Etoposide—lung cancer	0.000237	0.000494	CcSEcCtD
Epoprostenol—Decreased appetite—Paclitaxel—lung cancer	0.000236	0.000492	CcSEcCtD
Epoprostenol—Dry mouth—Docetaxel—lung cancer	0.000235	0.000489	CcSEcCtD
Epoprostenol—Haemoglobin—Methotrexate—lung cancer	0.000235	0.000489	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000234	0.000489	CcSEcCtD
Epoprostenol—Fatigue—Paclitaxel—lung cancer	0.000234	0.000488	CcSEcCtD
Epoprostenol—Haemorrhage—Methotrexate—lung cancer	0.000233	0.000487	CcSEcCtD
Epoprostenol—Asthenia—Gemcitabine—lung cancer	0.000233	0.000485	CcSEcCtD
Epoprostenol—Pain—Paclitaxel—lung cancer	0.000232	0.000484	CcSEcCtD
Epoprostenol—Constipation—Paclitaxel—lung cancer	0.000232	0.000484	CcSEcCtD
Epoprostenol—Confusional state—Docetaxel—lung cancer	0.000232	0.000484	CcSEcCtD
Epoprostenol—Pharyngitis—Methotrexate—lung cancer	0.000232	0.000483	CcSEcCtD
Epoprostenol—Anaphylactic shock—Docetaxel—lung cancer	0.00023	0.00048	CcSEcCtD
Epoprostenol—Oedema—Docetaxel—lung cancer	0.00023	0.00048	CcSEcCtD
Epoprostenol—Pruritus—Gemcitabine—lung cancer	0.000229	0.000478	CcSEcCtD
Epoprostenol—Infection—Docetaxel—lung cancer	0.000229	0.000477	CcSEcCtD
Epoprostenol—Weight decreased—Doxorubicin—lung cancer	0.000228	0.000476	CcSEcCtD
Epoprostenol—Diarrhoea—Irinotecan—lung cancer	0.000228	0.000475	CcSEcCtD
Epoprostenol—Pneumonia—Doxorubicin—lung cancer	0.000226	0.000472	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Etoposide—lung cancer	0.000226	0.000472	CcSEcCtD
Epoprostenol—Shock—Docetaxel—lung cancer	0.000226	0.000472	CcSEcCtD
Epoprostenol—Nervous system disorder—Docetaxel—lung cancer	0.000226	0.00047	CcSEcCtD
Epoprostenol—Thrombocytopenia—Docetaxel—lung cancer	0.000225	0.00047	CcSEcCtD
Epoprostenol—Infestation NOS—Doxorubicin—lung cancer	0.000225	0.000469	CcSEcCtD
Epoprostenol—Infestation—Doxorubicin—lung cancer	0.000225	0.000469	CcSEcCtD
Epoprostenol—Tachycardia—Docetaxel—lung cancer	0.000225	0.000468	CcSEcCtD
Epoprostenol—Skin disorder—Docetaxel—lung cancer	0.000223	0.000466	CcSEcCtD
Epoprostenol—Hypersensitivity—Cisplatin—lung cancer	0.000223	0.000464	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Paclitaxel—lung cancer	0.000222	0.000463	CcSEcCtD
Epoprostenol—Diarrhoea—Gemcitabine—lung cancer	0.000222	0.000463	CcSEcCtD
Epoprostenol—Dizziness—Irinotecan—lung cancer	0.00022	0.000459	CcSEcCtD
Epoprostenol—Urticaria—Etoposide—lung cancer	0.00022	0.000459	CcSEcCtD
Epoprostenol—Anorexia—Docetaxel—lung cancer	0.000219	0.000457	CcSEcCtD
Epoprostenol—Abdominal pain—Etoposide—lung cancer	0.000219	0.000456	CcSEcCtD
Epoprostenol—Body temperature increased—Etoposide—lung cancer	0.000219	0.000456	CcSEcCtD
Epoprostenol—Urinary tract infection—Doxorubicin—lung cancer	0.000219	0.000456	CcSEcCtD
Epoprostenol—Asthenia—Cisplatin—lung cancer	0.000217	0.000452	CcSEcCtD
Epoprostenol—Cardiac disorder—Methotrexate—lung cancer	0.000217	0.000452	CcSEcCtD
Epoprostenol—Sweating—Doxorubicin—lung cancer	0.000216	0.00045	CcSEcCtD
Epoprostenol—Urticaria—Paclitaxel—lung cancer	0.000216	0.00045	CcSEcCtD
Epoprostenol—Hypotension—Docetaxel—lung cancer	0.000215	0.000448	CcSEcCtD
Epoprostenol—Haematuria—Doxorubicin—lung cancer	0.000215	0.000448	CcSEcCtD
Epoprostenol—Abdominal pain—Paclitaxel—lung cancer	0.000215	0.000447	CcSEcCtD
Epoprostenol—Body temperature increased—Paclitaxel—lung cancer	0.000215	0.000447	CcSEcCtD
Epoprostenol—Epistaxis—Doxorubicin—lung cancer	0.000212	0.000443	CcSEcCtD
Epoprostenol—Angiopathy—Methotrexate—lung cancer	0.000212	0.000442	CcSEcCtD
Epoprostenol—Vomiting—Irinotecan—lung cancer	0.000212	0.000441	CcSEcCtD
Epoprostenol—Sinusitis—Doxorubicin—lung cancer	0.000211	0.00044	CcSEcCtD
Epoprostenol—Mediastinal disorder—Methotrexate—lung cancer	0.00021	0.000439	CcSEcCtD
Epoprostenol—Rash—Irinotecan—lung cancer	0.00021	0.000438	CcSEcCtD
Epoprostenol—Dermatitis—Irinotecan—lung cancer	0.00021	0.000437	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Docetaxel—lung cancer	0.00021	0.000437	CcSEcCtD
Epoprostenol—Chills—Methotrexate—lung cancer	0.000209	0.000437	CcSEcCtD
Epoprostenol—Headache—Irinotecan—lung cancer	0.000208	0.000435	CcSEcCtD
Epoprostenol—Insomnia—Docetaxel—lung cancer	0.000208	0.000434	CcSEcCtD
Epoprostenol—Diarrhoea—Cisplatin—lung cancer	0.000207	0.000431	CcSEcCtD
Epoprostenol—Paraesthesia—Docetaxel—lung cancer	0.000207	0.000431	CcSEcCtD
Epoprostenol—Vomiting—Gemcitabine—lung cancer	0.000206	0.00043	CcSEcCtD
Epoprostenol—Bradycardia—Doxorubicin—lung cancer	0.000206	0.000429	CcSEcCtD
Epoprostenol—Dyspnoea—Docetaxel—lung cancer	0.000205	0.000428	CcSEcCtD
Epoprostenol—Somnolence—Docetaxel—lung cancer	0.000205	0.000426	CcSEcCtD
Epoprostenol—Mental disorder—Methotrexate—lung cancer	0.000204	0.000426	CcSEcCtD
Epoprostenol—Rash—Gemcitabine—lung cancer	0.000204	0.000426	CcSEcCtD
Epoprostenol—Dermatitis—Gemcitabine—lung cancer	0.000204	0.000426	CcSEcCtD
Epoprostenol—Hypersensitivity—Etoposide—lung cancer	0.000204	0.000425	CcSEcCtD
Epoprostenol—Haemoglobin—Doxorubicin—lung cancer	0.000203	0.000424	CcSEcCtD
Epoprostenol—Headache—Gemcitabine—lung cancer	0.000203	0.000423	CcSEcCtD
Epoprostenol—Rhinitis—Doxorubicin—lung cancer	0.000203	0.000422	CcSEcCtD
Epoprostenol—Dyspepsia—Docetaxel—lung cancer	0.000202	0.000422	CcSEcCtD
Epoprostenol—Haemorrhage—Doxorubicin—lung cancer	0.000202	0.000421	CcSEcCtD
Epoprostenol—Hypoaesthesia—Doxorubicin—lung cancer	0.000201	0.000419	CcSEcCtD
Epoprostenol—Pharyngitis—Doxorubicin—lung cancer	0.000201	0.000418	CcSEcCtD
Epoprostenol—Decreased appetite—Docetaxel—lung cancer	0.0002	0.000417	CcSEcCtD
Epoprostenol—Hypersensitivity—Paclitaxel—lung cancer	0.0002	0.000417	CcSEcCtD
Epoprostenol—Oedema peripheral—Doxorubicin—lung cancer	0.000199	0.000415	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Docetaxel—lung cancer	0.000199	0.000414	CcSEcCtD
Epoprostenol—Asthenia—Etoposide—lung cancer	0.000199	0.000414	CcSEcCtD
Epoprostenol—Connective tissue disorder—Doxorubicin—lung cancer	0.000199	0.000414	CcSEcCtD
Epoprostenol—Fatigue—Docetaxel—lung cancer	0.000198	0.000414	CcSEcCtD
Epoprostenol—Nausea—Irinotecan—lung cancer	0.000198	0.000412	CcSEcCtD
Epoprostenol—Constipation—Docetaxel—lung cancer	0.000197	0.00041	CcSEcCtD
Epoprostenol—Pain—Docetaxel—lung cancer	0.000197	0.00041	CcSEcCtD
Epoprostenol—Back pain—Methotrexate—lung cancer	0.000197	0.00041	CcSEcCtD
Epoprostenol—Pruritus—Etoposide—lung cancer	0.000196	0.000408	CcSEcCtD
Epoprostenol—Asthenia—Paclitaxel—lung cancer	0.000195	0.000406	CcSEcCtD
Epoprostenol—Nausea—Gemcitabine—lung cancer	0.000193	0.000402	CcSEcCtD
Epoprostenol—Vomiting—Cisplatin—lung cancer	0.000192	0.000401	CcSEcCtD
Epoprostenol—Pruritus—Paclitaxel—lung cancer	0.000192	0.0004	CcSEcCtD
Epoprostenol—Rash—Cisplatin—lung cancer	0.000191	0.000397	CcSEcCtD
Epoprostenol—Dermatitis—Cisplatin—lung cancer	0.00019	0.000397	CcSEcCtD
Epoprostenol—Diarrhoea—Etoposide—lung cancer	0.000189	0.000395	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Docetaxel—lung cancer	0.000188	0.000392	CcSEcCtD
Epoprostenol—Anaemia—Methotrexate—lung cancer	0.000188	0.000392	CcSEcCtD
Epoprostenol—Cardiac disorder—Doxorubicin—lung cancer	0.000188	0.000391	CcSEcCtD
Epoprostenol—Flushing—Doxorubicin—lung cancer	0.000188	0.000391	CcSEcCtD
Epoprostenol—Diarrhoea—Paclitaxel—lung cancer	0.000186	0.000387	CcSEcCtD
Epoprostenol—Angiopathy—Doxorubicin—lung cancer	0.000183	0.000382	CcSEcCtD
Epoprostenol—Dizziness—Etoposide—lung cancer	0.000183	0.000382	CcSEcCtD
Epoprostenol—Mediastinal disorder—Doxorubicin—lung cancer	0.000182	0.00038	CcSEcCtD
Epoprostenol—Body temperature increased—Docetaxel—lung cancer	0.000182	0.000379	CcSEcCtD
Epoprostenol—Abdominal pain—Docetaxel—lung cancer	0.000182	0.000379	CcSEcCtD
Epoprostenol—Chills—Doxorubicin—lung cancer	0.000181	0.000378	CcSEcCtD
Epoprostenol—Dizziness—Paclitaxel—lung cancer	0.000179	0.000374	CcSEcCtD
Epoprostenol—Nausea—Cisplatin—lung cancer	0.000179	0.000374	CcSEcCtD
Epoprostenol—Cough—Methotrexate—lung cancer	0.000177	0.00037	CcSEcCtD
Epoprostenol—Mental disorder—Doxorubicin—lung cancer	0.000177	0.000369	CcSEcCtD
Epoprostenol—Vomiting—Etoposide—lung cancer	0.000176	0.000367	CcSEcCtD
Epoprostenol—Rash—Etoposide—lung cancer	0.000175	0.000364	CcSEcCtD
Epoprostenol—Dermatitis—Etoposide—lung cancer	0.000174	0.000364	CcSEcCtD
Epoprostenol—Headache—Etoposide—lung cancer	0.000173	0.000362	CcSEcCtD
Epoprostenol—Flatulence—Doxorubicin—lung cancer	0.000173	0.000361	CcSEcCtD
Epoprostenol—Myalgia—Methotrexate—lung cancer	0.000173	0.000361	CcSEcCtD
Epoprostenol—Arthralgia—Methotrexate—lung cancer	0.000173	0.000361	CcSEcCtD
Epoprostenol—Chest pain—Methotrexate—lung cancer	0.000173	0.000361	CcSEcCtD
Epoprostenol—Tension—Doxorubicin—lung cancer	0.000173	0.00036	CcSEcCtD
Epoprostenol—Vomiting—Paclitaxel—lung cancer	0.000173	0.00036	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.000172	0.000358	CcSEcCtD
Epoprostenol—Rash—Paclitaxel—lung cancer	0.000171	0.000357	CcSEcCtD
Epoprostenol—Dermatitis—Paclitaxel—lung cancer	0.000171	0.000357	CcSEcCtD
Epoprostenol—Nervousness—Doxorubicin—lung cancer	0.000171	0.000356	CcSEcCtD
Epoprostenol—Back pain—Doxorubicin—lung cancer	0.00017	0.000355	CcSEcCtD
Epoprostenol—Headache—Paclitaxel—lung cancer	0.00017	0.000355	CcSEcCtD
Epoprostenol—Hypersensitivity—Docetaxel—lung cancer	0.000169	0.000353	CcSEcCtD
Epoprostenol—Muscle spasms—Doxorubicin—lung cancer	0.000169	0.000353	CcSEcCtD
Epoprostenol—Confusional state—Methotrexate—lung cancer	0.000167	0.000349	CcSEcCtD
Epoprostenol—Anaphylactic shock—Methotrexate—lung cancer	0.000166	0.000346	CcSEcCtD
Epoprostenol—Asthenia—Docetaxel—lung cancer	0.000165	0.000344	CcSEcCtD
Epoprostenol—Infection—Methotrexate—lung cancer	0.000165	0.000343	CcSEcCtD
Epoprostenol—Nausea—Etoposide—lung cancer	0.000164	0.000343	CcSEcCtD
Epoprostenol—Pruritus—Docetaxel—lung cancer	0.000163	0.000339	CcSEcCtD
Epoprostenol—Nervous system disorder—Methotrexate—lung cancer	0.000163	0.000339	CcSEcCtD
Epoprostenol—Anaemia—Doxorubicin—lung cancer	0.000163	0.000339	CcSEcCtD
Epoprostenol—Thrombocytopenia—Methotrexate—lung cancer	0.000162	0.000339	CcSEcCtD
Epoprostenol—Agitation—Doxorubicin—lung cancer	0.000162	0.000337	CcSEcCtD
Epoprostenol—Nausea—Paclitaxel—lung cancer	0.000161	0.000336	CcSEcCtD
Epoprostenol—Skin disorder—Methotrexate—lung cancer	0.000161	0.000336	CcSEcCtD
Epoprostenol—Hyperhidrosis—Methotrexate—lung cancer	0.00016	0.000334	CcSEcCtD
Epoprostenol—Anorexia—Methotrexate—lung cancer	0.000158	0.00033	CcSEcCtD
Epoprostenol—Syncope—Doxorubicin—lung cancer	0.000158	0.000329	CcSEcCtD
Epoprostenol—Diarrhoea—Docetaxel—lung cancer	0.000157	0.000328	CcSEcCtD
Epoprostenol—Palpitations—Doxorubicin—lung cancer	0.000155	0.000324	CcSEcCtD
Epoprostenol—Hypotension—Methotrexate—lung cancer	0.000155	0.000323	CcSEcCtD
Epoprostenol—Loss of consciousness—Doxorubicin—lung cancer	0.000155	0.000322	CcSEcCtD
Epoprostenol—Cough—Doxorubicin—lung cancer	0.000154	0.00032	CcSEcCtD
Epoprostenol—Dizziness—Docetaxel—lung cancer	0.000152	0.000317	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Methotrexate—lung cancer	0.000151	0.000315	CcSEcCtD
Epoprostenol—Insomnia—Methotrexate—lung cancer	0.00015	0.000313	CcSEcCtD
Epoprostenol—Chest pain—Doxorubicin—lung cancer	0.00015	0.000312	CcSEcCtD
Epoprostenol—Arthralgia—Doxorubicin—lung cancer	0.00015	0.000312	CcSEcCtD
Epoprostenol—Myalgia—Doxorubicin—lung cancer	0.00015	0.000312	CcSEcCtD
Epoprostenol—Anxiety—Doxorubicin—lung cancer	0.000149	0.000311	CcSEcCtD
Epoprostenol—Paraesthesia—Methotrexate—lung cancer	0.000149	0.00031	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.000149	0.00031	CcSEcCtD
Epoprostenol—Dyspnoea—Methotrexate—lung cancer	0.000148	0.000308	CcSEcCtD
Epoprostenol—Somnolence—Methotrexate—lung cancer	0.000147	0.000307	CcSEcCtD
Epoprostenol—Dry mouth—Doxorubicin—lung cancer	0.000146	0.000305	CcSEcCtD
Epoprostenol—Vomiting—Docetaxel—lung cancer	0.000146	0.000305	CcSEcCtD
Epoprostenol—Dyspepsia—Methotrexate—lung cancer	0.000146	0.000304	CcSEcCtD
Epoprostenol—Rash—Docetaxel—lung cancer	0.000145	0.000302	CcSEcCtD
Epoprostenol—Dermatitis—Docetaxel—lung cancer	0.000145	0.000302	CcSEcCtD
Epoprostenol—Confusional state—Doxorubicin—lung cancer	0.000145	0.000302	CcSEcCtD
Epoprostenol—Decreased appetite—Methotrexate—lung cancer	0.000144	0.000301	CcSEcCtD
Epoprostenol—Headache—Docetaxel—lung cancer	0.000144	0.000301	CcSEcCtD
Epoprostenol—Anaphylactic shock—Doxorubicin—lung cancer	0.000144	0.000299	CcSEcCtD
Epoprostenol—Oedema—Doxorubicin—lung cancer	0.000144	0.000299	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Methotrexate—lung cancer	0.000143	0.000298	CcSEcCtD
Epoprostenol—Fatigue—Methotrexate—lung cancer	0.000143	0.000298	CcSEcCtD
Epoprostenol—Infection—Doxorubicin—lung cancer	0.000143	0.000297	CcSEcCtD
Epoprostenol—Pain—Methotrexate—lung cancer	0.000142	0.000296	CcSEcCtD
Epoprostenol—Shock—Doxorubicin—lung cancer	0.000141	0.000295	CcSEcCtD
Epoprostenol—Nervous system disorder—Doxorubicin—lung cancer	0.000141	0.000294	CcSEcCtD
Epoprostenol—Thrombocytopenia—Doxorubicin—lung cancer	0.000141	0.000293	CcSEcCtD
Epoprostenol—Tachycardia—Doxorubicin—lung cancer	0.00014	0.000292	CcSEcCtD
Epoprostenol—Skin disorder—Doxorubicin—lung cancer	0.000139	0.000291	CcSEcCtD
Epoprostenol—Hyperhidrosis—Doxorubicin—lung cancer	0.000139	0.000289	CcSEcCtD
Epoprostenol—Anorexia—Doxorubicin—lung cancer	0.000137	0.000285	CcSEcCtD
Epoprostenol—Nausea—Docetaxel—lung cancer	0.000137	0.000285	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Methotrexate—lung cancer	0.000136	0.000283	CcSEcCtD
Epoprostenol—Hypotension—Doxorubicin—lung cancer	0.000134	0.00028	CcSEcCtD
Epoprostenol—Urticaria—Methotrexate—lung cancer	0.000132	0.000275	CcSEcCtD
Epoprostenol—Abdominal pain—Methotrexate—lung cancer	0.000131	0.000273	CcSEcCtD
Epoprostenol—Body temperature increased—Methotrexate—lung cancer	0.000131	0.000273	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Doxorubicin—lung cancer	0.000131	0.000273	CcSEcCtD
Epoprostenol—Insomnia—Doxorubicin—lung cancer	0.00013	0.000271	CcSEcCtD
Epoprostenol—Paraesthesia—Doxorubicin—lung cancer	0.000129	0.000269	CcSEcCtD
Epoprostenol—Dyspnoea—Doxorubicin—lung cancer	0.000128	0.000267	CcSEcCtD
Epoprostenol—Somnolence—Doxorubicin—lung cancer	0.000128	0.000266	CcSEcCtD
Epoprostenol—Dyspepsia—Doxorubicin—lung cancer	0.000126	0.000264	CcSEcCtD
Epoprostenol—Decreased appetite—Doxorubicin—lung cancer	0.000125	0.00026	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000124	0.000258	CcSEcCtD
Epoprostenol—Fatigue—Doxorubicin—lung cancer	0.000124	0.000258	CcSEcCtD
Epoprostenol—Pain—Doxorubicin—lung cancer	0.000123	0.000256	CcSEcCtD
Epoprostenol—Constipation—Doxorubicin—lung cancer	0.000123	0.000256	CcSEcCtD
Epoprostenol—Hypersensitivity—Methotrexate—lung cancer	0.000122	0.000255	CcSEcCtD
Epoprostenol—Asthenia—Methotrexate—lung cancer	0.000119	0.000248	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Doxorubicin—lung cancer	0.000117	0.000245	CcSEcCtD
Epoprostenol—Pruritus—Methotrexate—lung cancer	0.000117	0.000245	CcSEcCtD
Epoprostenol—Urticaria—Doxorubicin—lung cancer	0.000114	0.000238	CcSEcCtD
Epoprostenol—Body temperature increased—Doxorubicin—lung cancer	0.000113	0.000237	CcSEcCtD
Epoprostenol—Abdominal pain—Doxorubicin—lung cancer	0.000113	0.000237	CcSEcCtD
Epoprostenol—Diarrhoea—Methotrexate—lung cancer	0.000113	0.000237	CcSEcCtD
Epoprostenol—Dizziness—Methotrexate—lung cancer	0.00011	0.000229	CcSEcCtD
Epoprostenol—Hypersensitivity—Doxorubicin—lung cancer	0.000106	0.000221	CcSEcCtD
Epoprostenol—Vomiting—Methotrexate—lung cancer	0.000105	0.00022	CcSEcCtD
Epoprostenol—Rash—Methotrexate—lung cancer	0.000105	0.000218	CcSEcCtD
Epoprostenol—Dermatitis—Methotrexate—lung cancer	0.000104	0.000218	CcSEcCtD
Epoprostenol—Headache—Methotrexate—lung cancer	0.000104	0.000217	CcSEcCtD
Epoprostenol—Asthenia—Doxorubicin—lung cancer	0.000103	0.000215	CcSEcCtD
Epoprostenol—Pruritus—Doxorubicin—lung cancer	0.000102	0.000212	CcSEcCtD
Epoprostenol—Nausea—Methotrexate—lung cancer	9.85e-05	0.000205	CcSEcCtD
Epoprostenol—Diarrhoea—Doxorubicin—lung cancer	9.82e-05	0.000205	CcSEcCtD
Epoprostenol—Dizziness—Doxorubicin—lung cancer	9.49e-05	0.000198	CcSEcCtD
Epoprostenol—Vomiting—Doxorubicin—lung cancer	9.13e-05	0.00019	CcSEcCtD
Epoprostenol—Rash—Doxorubicin—lung cancer	9.05e-05	0.000189	CcSEcCtD
Epoprostenol—Dermatitis—Doxorubicin—lung cancer	9.04e-05	0.000189	CcSEcCtD
Epoprostenol—Headache—Doxorubicin—lung cancer	8.99e-05	0.000188	CcSEcCtD
Epoprostenol—Nausea—Doxorubicin—lung cancer	8.53e-05	0.000178	CcSEcCtD
Epoprostenol—PTGIS—Disease—CDKN1A—lung cancer	5.8e-05	0.000196	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—IL2—lung cancer	5.8e-05	0.000196	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—lung cancer	5.79e-05	0.000196	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PTEN—lung cancer	5.79e-05	0.000196	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TERT—lung cancer	5.78e-05	0.000195	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—HRAS—lung cancer	5.71e-05	0.000193	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—FGFR1—lung cancer	5.61e-05	0.00019	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PIK3CB—lung cancer	5.61e-05	0.00019	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—CXCL8—lung cancer	5.59e-05	0.000189	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CXCL8—lung cancer	5.59e-05	0.000189	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PTGS2—lung cancer	5.56e-05	0.000188	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ERBB3—lung cancer	5.55e-05	0.000188	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ERBB3—lung cancer	5.55e-05	0.000188	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—HIF1A—lung cancer	5.53e-05	0.000187	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—EP300—lung cancer	5.52e-05	0.000187	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—AKT1—lung cancer	5.48e-05	0.000185	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HSD17B10—lung cancer	5.38e-05	0.000182	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—SRC—lung cancer	5.37e-05	0.000181	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—IL2—lung cancer	5.34e-05	0.00018	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—IL2—lung cancer	5.34e-05	0.00018	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—APOA1—lung cancer	5.33e-05	0.00018	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TERT—lung cancer	5.32e-05	0.00018	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TERT—lung cancer	5.32e-05	0.00018	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—KDR—lung cancer	5.29e-05	0.000179	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—STAT3—lung cancer	5.18e-05	0.000175	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—NRAS—lung cancer	5.16e-05	0.000175	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—FGFR1—lung cancer	5.16e-05	0.000174	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—FGFR1—lung cancer	5.16e-05	0.000174	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—HIF1A—lung cancer	5.09e-05	0.000172	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—HIF1A—lung cancer	5.09e-05	0.000172	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—AKT1—lung cancer	5.04e-05	0.00017	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CKB—lung cancer	5.01e-05	0.000169	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MAPK3—lung cancer	4.95e-05	0.000167	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—APOA1—lung cancer	4.91e-05	0.000166	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—APOA1—lung cancer	4.91e-05	0.000166	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CG—lung cancer	4.87e-05	0.000165	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—APC—lung cancer	4.87e-05	0.000165	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—KIT—lung cancer	4.87e-05	0.000165	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—NRAS—lung cancer	4.87e-05	0.000165	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—KDR—lung cancer	4.86e-05	0.000164	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—KDR—lung cancer	4.86e-05	0.000164	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PTEN—lung cancer	4.85e-05	0.000164	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—EGF—lung cancer	4.81e-05	0.000163	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MYC—lung cancer	4.81e-05	0.000163	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTM2—lung cancer	4.71e-05	0.000159	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CNDP2—lung cancer	4.71e-05	0.000159	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—EGFR—lung cancer	4.7e-05	0.000159	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—MAPK3—lung cancer	4.66e-05	0.000158	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—POMC—lung cancer	4.63e-05	0.000157	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—EP300—lung cancer	4.62e-05	0.000156	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—MTMR3—lung cancer	4.58e-05	0.000155	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—BRAF—lung cancer	4.58e-05	0.000155	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL6R—lung cancer	4.52e-05	0.000153	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CREBBP—lung cancer	4.51e-05	0.000153	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CG—lung cancer	4.48e-05	0.000151	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—KIT—lung cancer	4.48e-05	0.000151	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—APC—lung cancer	4.48e-05	0.000151	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—APC—lung cancer	4.48e-05	0.000151	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CG—lung cancer	4.48e-05	0.000151	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—KIT—lung cancer	4.48e-05	0.000151	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—NRAS—lung cancer	4.48e-05	0.000151	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—NRAS—lung cancer	4.48e-05	0.000151	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PGAM1—lung cancer	4.46e-05	0.000151	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—KRAS—lung cancer	4.44e-05	0.00015	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—EGFR—lung cancer	4.44e-05	0.00015	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—EGF—lung cancer	4.43e-05	0.00015	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—EGF—lung cancer	4.43e-05	0.00015	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MAP2K1—lung cancer	4.31e-05	0.000146	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—MAPK3—lung cancer	4.29e-05	0.000145	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—MAPK3—lung cancer	4.29e-05	0.000145	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CD—lung cancer	4.28e-05	0.000145	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—POMC—lung cancer	4.27e-05	0.000144	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—POMC—lung cancer	4.27e-05	0.000144	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP2A7—lung cancer	4.26e-05	0.000144	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—PIK3CA—lung cancer	4.24e-05	0.000143	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—BRAF—lung cancer	4.21e-05	0.000142	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—BRAF—lung cancer	4.21e-05	0.000142	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—KRAS—lung cancer	4.19e-05	0.000142	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SDC4—lung cancer	4.17e-05	0.000141	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL6R—lung cancer	4.16e-05	0.000141	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL6R—lung cancer	4.16e-05	0.000141	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CREBBP—lung cancer	4.15e-05	0.00014	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CREBBP—lung cancer	4.15e-05	0.00014	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PIK3CA—lung cancer	4.08e-05	0.000138	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—EGFR—lung cancer	4.08e-05	0.000138	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—EGFR—lung cancer	4.08e-05	0.000138	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MAP2K1—lung cancer	3.97e-05	0.000134	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MAP2K1—lung cancer	3.97e-05	0.000134	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CD—lung cancer	3.94e-05	0.000133	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CD—lung cancer	3.94e-05	0.000133	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—PIK3CA—lung cancer	3.9e-05	0.000132	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—PIK3CA—lung cancer	3.9e-05	0.000132	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—KRAS—lung cancer	3.86e-05	0.00013	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—KRAS—lung cancer	3.86e-05	0.00013	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—PIK3CA—lung cancer	3.85e-05	0.00013	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MDM2—lung cancer	3.83e-05	0.00013	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—RAF1—lung cancer	3.82e-05	0.000129	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—RRM1—lung cancer	3.79e-05	0.000128	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTA3—lung cancer	3.79e-05	0.000128	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—ERBB2—lung cancer	3.78e-05	0.000128	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—HRAS—lung cancer	3.78e-05	0.000128	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CB—lung cancer	3.73e-05	0.000126	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MTOR—lung cancer	3.73e-05	0.000126	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—IL6—lung cancer	3.62e-05	0.000122	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CXCL8—lung cancer	3.59e-05	0.000121	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—B4GALT5—lung cancer	3.57e-05	0.000121	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—HRAS—lung cancer	3.56e-05	0.00012	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PIK3CA—lung cancer	3.54e-05	0.00012	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—PIK3CA—lung cancer	3.54e-05	0.00012	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MDM2—lung cancer	3.53e-05	0.000119	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MDM2—lung cancer	3.53e-05	0.000119	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—RAF1—lung cancer	3.52e-05	0.000119	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—RAF1—lung cancer	3.52e-05	0.000119	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ERBB2—lung cancer	3.48e-05	0.000118	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ERBB2—lung cancer	3.48e-05	0.000118	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTA4—lung cancer	3.47e-05	0.000117	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—AKT1—lung cancer	3.46e-05	0.000117	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MTOR—lung cancer	3.43e-05	0.000116	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CB—lung cancer	3.43e-05	0.000116	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CB—lung cancer	3.43e-05	0.000116	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MTOR—lung cancer	3.43e-05	0.000116	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CASP3—lung cancer	3.43e-05	0.000116	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL2—lung cancer	3.43e-05	0.000116	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PIK3CA—lung cancer	3.42e-05	0.000116	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—IL6—lung cancer	3.41e-05	0.000115	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—lung cancer	3.39e-05	0.000115	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTA2—lung cancer	3.38e-05	0.000114	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CCND1—lung cancer	3.34e-05	0.000113	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—AKT1—lung cancer	3.34e-05	0.000113	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—JUN—lung cancer	3.33e-05	0.000113	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CXCL8—lung cancer	3.3e-05	0.000111	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CXCL8—lung cancer	3.3e-05	0.000111	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—HRAS—lung cancer	3.28e-05	0.000111	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—HRAS—lung cancer	3.28e-05	0.000111	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTA1—lung cancer	3.26e-05	0.00011	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MMP9—lung cancer	3.24e-05	0.00011	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CDKN1A—lung cancer	3.23e-05	0.000109	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ABCC3—lung cancer	3.23e-05	0.000109	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PTEN—lung cancer	3.22e-05	0.000109	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—AKT1—lung cancer	3.19e-05	0.000108	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—AKT1—lung cancer	3.19e-05	0.000108	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CASP3—lung cancer	3.16e-05	0.000107	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CASP3—lung cancer	3.16e-05	0.000107	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL2—lung cancer	3.15e-05	0.000107	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL2—lung cancer	3.15e-05	0.000107	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—AKT1—lung cancer	3.14e-05	0.000106	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—IL6—lung cancer	3.14e-05	0.000106	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—IL6—lung cancer	3.14e-05	0.000106	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—AKR1C1—lung cancer	3.12e-05	0.000106	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—EP300—lung cancer	3.07e-05	0.000104	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCND1—lung cancer	3.07e-05	0.000104	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CCND1—lung cancer	3.07e-05	0.000104	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—JUN—lung cancer	3.07e-05	0.000104	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—JUN—lung cancer	3.07e-05	0.000104	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—UGT1A1—lung cancer	3.03e-05	0.000102	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—SRC—lung cancer	2.99e-05	0.000101	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MMP9—lung cancer	2.98e-05	0.000101	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MMP9—lung cancer	2.98e-05	0.000101	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CDKN1A—lung cancer	2.97e-05	0.0001	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CDKN1A—lung cancer	2.97e-05	0.0001	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PTEN—lung cancer	2.97e-05	0.0001	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PTEN—lung cancer	2.97e-05	0.0001	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GNG11—lung cancer	2.92e-05	9.88e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—VEGFA—lung cancer	2.91e-05	9.84e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—lung cancer	2.91e-05	9.83e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—AKT1—lung cancer	2.89e-05	9.78e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—AKT1—lung cancer	2.89e-05	9.78e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—STAT3—lung cancer	2.88e-05	9.74e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NRAS—lung cancer	2.88e-05	9.72e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—EP300—lung cancer	2.83e-05	9.56e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—EP300—lung cancer	2.83e-05	9.56e-05	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—AKT1—lung cancer	2.79e-05	9.44e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ALDOA—lung cancer	2.78e-05	9.41e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MAPK3—lung cancer	2.75e-05	9.31e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SRC—lung cancer	2.75e-05	9.3e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SRC—lung cancer	2.75e-05	9.3e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NCOA3—lung cancer	2.7e-05	9.13e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—VEGFA—lung cancer	2.68e-05	9.06e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—VEGFA—lung cancer	2.68e-05	9.06e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MYC—lung cancer	2.68e-05	9.05e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	2.66e-05	8.98e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—STAT3—lung cancer	2.65e-05	8.97e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—STAT3—lung cancer	2.65e-05	8.97e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NRAS—lung cancer	2.65e-05	8.94e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NRAS—lung cancer	2.65e-05	8.94e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ADCY1—lung cancer	2.63e-05	8.89e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ABCG2—lung cancer	2.63e-05	8.89e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—EGFR—lung cancer	2.62e-05	8.85e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HPGDS—lung cancer	2.58e-05	8.71e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ENO2—lung cancer	2.58e-05	8.71e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PPP2R1B—lung cancer	2.56e-05	8.66e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MAPK3—lung cancer	2.53e-05	8.57e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MAPK3—lung cancer	2.53e-05	8.57e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—POMC—lung cancer	2.53e-05	8.54e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTT1—lung cancer	2.5e-05	8.45e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—KRAS—lung cancer	2.48e-05	8.36e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GCLC—lung cancer	2.47e-05	8.35e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP2A6—lung cancer	2.47e-05	8.35e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MYC—lung cancer	2.47e-05	8.33e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MYC—lung cancer	2.47e-05	8.33e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	2.46e-05	8.32e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—EGFR—lung cancer	2.41e-05	8.15e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—EGFR—lung cancer	2.41e-05	8.15e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ENO1—lung cancer	2.34e-05	7.92e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	2.34e-05	7.89e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—lung cancer	2.31e-05	7.79e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—KRAS—lung cancer	2.28e-05	7.7e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—KRAS—lung cancer	2.28e-05	7.7e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CA—lung cancer	2.27e-05	7.69e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TP53—lung cancer	2.2e-05	7.43e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—HRAS—lung cancer	2.1e-05	7.11e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP2E1—lung cancer	2.1e-05	7.1e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CA—lung cancer	2.09e-05	7.07e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CA—lung cancer	2.09e-05	7.07e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NQO1—lung cancer	2.08e-05	7.02e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	2.04e-05	6.88e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TP53—lung cancer	2.02e-05	6.84e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TP53—lung cancer	2.02e-05	6.84e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	2.02e-05	6.82e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL6—lung cancer	2.01e-05	6.81e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—HRAS—lung cancer	1.94e-05	6.54e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—HRAS—lung cancer	1.94e-05	6.54e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—STK11—lung cancer	1.87e-05	6.33e-05	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—AKT1—lung cancer	1.86e-05	6.28e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL6—lung cancer	1.85e-05	6.26e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL6—lung cancer	1.85e-05	6.26e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—lung cancer	1.76e-05	5.94e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTP1—lung cancer	1.73e-05	5.86e-05	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—AKT1—lung cancer	1.71e-05	5.78e-05	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—AKT1—lung cancer	1.71e-05	5.78e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CAT—lung cancer	1.69e-05	5.7e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—EP300—lung cancer	1.68e-05	5.67e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ABCB1—lung cancer	1.64e-05	5.55e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—TYMS—lung cancer	1.61e-05	5.45e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GSTM1—lung cancer	1.59e-05	5.38e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CYP1A1—lung cancer	1.51e-05	5.1e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ERCC2—lung cancer	1.5e-05	5.06e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—APOA1—lung cancer	1.3e-05	4.38e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	1.24e-05	4.19e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CG—lung cancer	1.18e-05	4e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—POMC—lung cancer	1.13e-05	3.81e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CREBBP—lung cancer	1.1e-05	3.71e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CD—lung cancer	1.04e-05	3.51e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ALB—lung cancer	1.03e-05	3.47e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CB—lung cancer	9.06e-06	3.06e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PTGS2—lung cancer	8.98e-06	3.04e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PTEN—lung cancer	7.83e-06	2.65e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—EP300—lung cancer	7.47e-06	2.52e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CA—lung cancer	5.53e-06	1.87e-05	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—AKT1—lung cancer	4.51e-06	1.53e-05	CbGpPWpGaD
